CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for New Horizon Health Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

New Horizon Health Ltd
13/F, T1 Building
400 Jiang'er Road
HANGZHOU, ZHJ  China Ticker: 66066606
Business Summary
New Horizon Health Ltd is an investment holding company principally engaged in developing and commercializing innovative cancer screening products. The Company is primarily engaged in the research and development, clinical development, test operation and commercialization of screening products for colorectal cancer, gastric cancer, cervical cancer and others. The Company’s main products include home-based colorectal cancer screening tests ColoClear and Pupu Tube, stool-based self-conducted screening product for H. pylori UU Tube, and non-invasive urine-based home-use screening test for cervical cancer CerviClear. The Company mainly conducts its businesses in the domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
5047 Medical, dental, and hospital equipment and supplies
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board NaxinYao 54 12/30/2024 10/9/2020
Chief Financial Officer Yiau ChongChoi 50 11/1/2024 11/1/2024
Chief Technology Officer NingLu 52 11/19/2015 11/19/2015
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,041 (As of 6/30/2023)
Outstanding Shares: 448,754,608 (As of 3/3/2025)
Stock Exchange: HKG


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025